Personalis
Personalis is a company specializing in advanced genomic testing and liquid biopsy approaches for cancer detection, biomarker discovery, and clinical research. They focus on innovative sequencing technologies and comprehensive tumor profiling to support personalized medicine and cancer research.
Industries
Nr. of Employees
medium (51-250)
Personalis
Patents
Methods for using mosaicism in nucleic acids sampled distal to their origin
US-12270083-B2
View Details
Methods for using mosaicism in nucleic acids sampled distal to their origin
US-12270083-B2
View DetailsProducts
Immunogenomic discovery platform (NGS-based)
A sequencing and computational platform that combines immunogenomic assays and neoantigen prediction to support biomarker discovery and immunotherapy research.
NeXT Personal® Dx
An ultra-sensitive tumor-informed liquid biopsy assay designed to detect molecular residual disease (MRD) at ultra-low levels, track responses to therapy, and identify clinically relevant variants.
ImmunoID NeXT
ImmunoID NeXT combines multiple biomarker assays into one, simultaneously solving logistical and technical problems for clinical trial sponsors by elucidating tumor-immune interactions from a single sample.
ACE ImmunoID
ACE ImmunoID is an analytically-validated whole exome and transcriptome sequencing platform using matched tumor and normal samples, developed for use with our RUO neoantigen prediction analysis pipeline.
NeXT Liquid Biopsy
High-performance whole exome sequencing liquid biopsy assay from plasma providing comprehensive tumor profiling and longitudinal monitoring.
NeoantigenID
An analytical module of the ImmunoID NeXT Platform providing comprehensive identification of putative neoantigens using augmented exome and transcriptome sequencing data.
Immunogenomic discovery platform (NGS-based)
A sequencing and computational platform that combines immunogenomic assays and neoantigen prediction to support biomarker discovery and immunotherapy research.
NeXT Personal® Dx
An ultra-sensitive tumor-informed liquid biopsy assay designed to detect molecular residual disease (MRD) at ultra-low levels, track responses to therapy, and identify clinically relevant variants.
ImmunoID NeXT
ImmunoID NeXT combines multiple biomarker assays into one, simultaneously solving logistical and technical problems for clinical trial sponsors by elucidating tumor-immune interactions from a single sample.
ACE ImmunoID
ACE ImmunoID is an analytically-validated whole exome and transcriptome sequencing platform using matched tumor and normal samples, developed for use with our RUO neoantigen prediction analysis pipeline.
NeXT Liquid Biopsy
High-performance whole exome sequencing liquid biopsy assay from plasma providing comprehensive tumor profiling and longitudinal monitoring.
NeoantigenID
An analytical module of the ImmunoID NeXT Platform providing comprehensive identification of putative neoantigens using augmented exome and transcriptome sequencing data.
Services
Laboratory-based cfDNA extraction, targeted sequencing, and analytical reporting for ctDNA-based cancer detection and monitoring.
Comprehensive tumor sequencing using augmented NGS to identify somatic variants, copy-number changes, and other genomic features for research or clinical use.
End-to-end neoantigen identification and prioritization from tumor and normal sequencing data to support immunotherapy development.
Assay and data workflows for discovery of genomic and immune biomarkers in solid and hematologic cancers, including custom study designs.
Validation studies and performance qualification for NGS assays and discovery platforms, including reproducibility and accuracy assessments.
Sequencing operations and data services structured to meet clinical trial workflows, including sample handling, sequencing, and result delivery.
Laboratory-based cfDNA extraction, targeted sequencing, and analytical reporting for ctDNA-based cancer detection and monitoring.
Comprehensive tumor sequencing using augmented NGS to identify somatic variants, copy-number changes, and other genomic features for research or clinical use.
End-to-end neoantigen identification and prioritization from tumor and normal sequencing data to support immunotherapy development.
Assay and data workflows for discovery of genomic and immune biomarkers in solid and hematologic cancers, including custom study designs.
Validation studies and performance qualification for NGS assays and discovery platforms, including reproducibility and accuracy assessments.
Sequencing operations and data services structured to meet clinical trial workflows, including sample handling, sequencing, and result delivery.
Expertise Areas
- Liquid biopsy and circulating tumor DNA analysis
- Tumor genomic profiling and characterization
- Neoantigen discovery and immunogenomics
- NGS assay design and validation
Key Technologies
- Next-generation sequencing (NGS)
- Cell-free DNA (cfDNA) / circulating tumor DNA (ctDNA) analysis
- Targeted oncology gene panels
- Neoantigen prediction algorithms